MedTrace Logo

Effects of Anti-IgE Antibody Omalizumab on Patients With Chronic Sinusitis

NCT00603785 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2020-02-05

No results posted yet for this study

Summary

We propose to study the effects of Xolair on patients with chronic sinusitis with or without nasal polyps. Because of the similarities between the inflammatory processes found in asthmas and rhinitis to those found in chronic sinusitis, we hypothesize that sinusitis should respond to Xolair, just as asthma.

Conditions

  • Chronic Sinusitis

Interventions

DRUG

Placebo

Subjects with chronic sinusitis and evidence of atopy and an elevated total IgE (\>30 and \<700 IU/ml) will be randomized to receive placebo treatment for 6 months.

DRUG

Xolair

Subjects with chronic sinusitis and evidence of atopy and an elevated total IgE (\>30 and \<700 IU/ml) will be randomized to receive Xolair treatment for 6 months.

Sponsors & Collaborators

Principal Investigators

  • Andrew Goldberg, MD · University of California, San Francisco

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2008-04-30
Completion
2008-04-30

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00603785 on ClinicalTrials.gov